The current study now extends the literature by showing that this concept similarly applies to the combined administration of exenatide and basal insulin in early T2DM (a setting in which exogenous insulin offers sustained metabolic effects that exenatide does not further enhance). Here, INS is linked to type 2 diabetes mellitus.